Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
163
resultados
Última actualización
20/03/2026 [07:34:00]
Resultados 75 a 100 de 163
Resumen de: US20260035342A1
There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment and amyloid-β related diseases, such as Alzheimer's disease.
Resumen de: US20260034085A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US20260034088A1
Provided herein is the use of a compound of Formula I:or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Resumen de: US20260034233A1
Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Resumen de: US20260035414A1
The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and/or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and/or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and/or by a decrease in the duration of such symptoms.
Resumen de: US20260035387A1
The present disclosure provides a compound of Formula (I′), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein (“mHTT”) in a subject is of therapeutic benefit, specifically in treating Huntington disease (“HD”). This disclosure also features a composition containing the same as well as methods of using and making the same.
Resumen de: US20260034121A1
Provided herein are compounds, compositions, and methods for inhibiting fibril growth. Compositions include at least one alpha-Synuclein (aSyn) inhibiting agent in the form of a compound including a dimethyoxyphenyl piperazine group. Methods include inhibiting aSyn fibril growth and treating a neurodegenerative disease in a subject in need thereof, including Parkinson's Disease and Lewy Body disease (LBD). Methods including administering a composition of the present disclosure. Further provided is a system for detecting aSyn fibril growth in a subject in need thereof, the system including a fluorescence screening assay of the present disclosure.
Resumen de: US20260034109A1
Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine or pharmaceutically acceptable salt thereof.
Resumen de: US20260034143A1
Compositions of Allopregnanolone (Allo), and methods of use thereof for treating and preventing Alzheimer's Disease (AD) or dementia have been developed. In some embodiments, the amount of Allo effective to treat AD or dementia is between about 2 mg and about 10 mg, preferably 4 mg per dose. Methods for identifying subjects for treatment of AD or dementia are also provided. The methods include selecting a subject having one or more Apo E4 gene alleles. Methods of treating a human subject having AD or at risk of AD OR DEMENTIA are provided. The methods include administering a dosage of from 2 mg to 6 mg to the subject once within a 24 hour period. The dosing is repeated every seven days, or less frequently. The methods stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes.
Resumen de: EP4686476A1
The invention refers to the field of neurodegenerative diseases including Alzheimer's Disease and a treatment thereof with a Benzoxazepine compound. Benzoxazepine compounds are e.g. known in the treatment of breast cancer and according to the use of the invention are a first therapeutic and prophylactic treatment for neurodegenerative diseases, including Alzheimer's Disease.The invention further relates to test systems for identifying, mapping, elaborating and evaluating said and further therapeutic and prophylactic uses of compounds of interest and/or other pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's Disease. (AD)
Resumen de: MX2025013613A
Disclosed are methods of treating amyotrophic lateral sclerosis (ALS). Also disclosed are methods of treating C9orf72 amyotrophic lateral sclerosis (C9-ALS).
Resumen de: MX2025013536A
The present invention is related to the biomedical and biopharmaceutical sectors. Specifically, it relates to a chimeric antigen comprising the combination of the amino and carboxyl terminal regions of the amyloid beta peptide (Aβ), the amino and carboxyl terminal regions of the tau protein and a T cell epitope. The pharmaceutical composition comprising this chimeric antigen and at least one pharmaceutically acceptable vaccine adjuvant increases the efficacy of immunotherapy for the prevention and treatment of Alzheimer's Disease (AD). The chimeric antigen exerts its action by stimulating a multitarget humoral response with high titers of anti-Aβ and anti-tau antibodies simultaneously. This favors the combined elimination of toxic species of both Aβ and tau from the brain, which prevents or significantly improves the clinical symptoms and neuropathology of AD.
Resumen de: MX2025012789A
The present disclosure relates, in part, to compounds of Formula (I) and (II), which selectively inhibit JUN N-Terminal Kinases (JNK1, JNK2, and/or JNK3; also known as MAPK8, MAPK9, and/or MAPK10), pharmaceutical compositions thereof, and methods of using the same for the treatment, prevention, and/or amelioration of one or more diseases and/or disorders in a subject. In certain embodiments, the inflammatory disease or disorder is endometriosis, arthritis, pulmonary fibrosis, cancer, type 1 and/or 2 diabetes, Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis. In certain embodiments, the methods described herein further comprise detecting the disease and/or disorder in the subject with a suitable diagnostic method.
Resumen de: MX2025012735A
Provided herein are methods of treating diseases and disorders related to TDP-43 aggregation (e.g., ALS) with an antibody that specifically binds to OxPC or a polynucleotide encoding an antibody that specifically binds to OxPC.
Resumen de: MX2025007688A
Compounds, compositions, uses, and methods for increasing cell viability of a dopaminergic neuron, or for preventing or treating dopaminergic neuronal death, are provided herein. In certain examples, methods for reducing symptoms and/or for preventing or treating Parkinson's disease in a subject in need thereof are provided which may include a step of treatment with a GDP-bound form of Rab1a (Rab1a<sup>GDP</sup>), one or more expressible nucleic acids encoding Rab1a<sup>GDP</sup>, or a combination thereof.
Resumen de: AU2024307361A1
Described herein are crystalline forms of 6-(6-(((1R,2R,3S,5S)-2-fluoro-9-azabicyclo3.3.1nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzodoxazol-5-ol (compound A), a small molecule splicing modulator (SMSM) of mRNA, such as pre-mRNA, encoded by genes, for the treatment of Huntington's disease.
Resumen de: NZ812405A
A levodopa derivative including a compound or pharmaceutically acceptable salt, hydrate, and/or solvate thereof, wherein the compound includes substituents which, in aggregate, contain at least 6 carbon atoms which are only bonded to either other carbon atoms or to hydrogen atoms. The levodopa derivative may be formulated as a composition including one or more pharmaceutically acceptable carriers or excipients. The levodopa derivative may be part of a pharmaceutical composition including micro or nano particles in which the levodopa derivative is encapsulated in the pharmaceutically acceptable polymer. The levodopa derivative can be used to treat Parkinson’s disease by administering to a mammal an amount sufficient to treat Parkinson’s disease.
Resumen de: CN121422010A
The invention relates to the field of natural product pharmacy, in particular to an acetylcholin esterase inhibitor sourced from a natural product and application of the acetylcholin esterase inhibitor. Although a chemical synthetic acetylcholin esterase inhibitor used in clinical treatment at present achieves a certain curative effect, the chemical synthetic acetylcholin esterase inhibitor still has the problems of side effects, drug resistance and the like. Therefore, the invention provides the acetylcholin esterase inhibitor, the inhibitor is a single-drug or double-drug composition derived from natural products, the single drug is grifolin isoflavone (TI) or isoeugenol acetate (IA), and the double drug is prepared from TI and IA in proportion. The acetylcholin esterase inhibitor disclosed by the invention has good AChE inhibitory activity, anti-Abeta aggregation effect, antioxidant activity and good neuroprotection effect, and the TI and/or IA can be used as a novel acetylcholin esterase inhibitor to be applied to the development and use of medicines for clinically treating and/or preventing related diseases such as Alzheimer's disease.
Resumen de: CN121443318A
The present invention provides a method of treating a neurodegenerative disease. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate or nanocomposite, the nanocomposites have an outer shell comprising one or more polymer-flavonoid conjugates and, optionally, an inner shell comprising one or more flavonoid oligomers, as well as drugs, such as anti-CD3 or anti-CD33, encapsulated within these shells. The methods of the invention allow therapeutically effective substances to pass through the blood-brain barrier to treat neurodegenerative diseases. The methods of the invention are effective in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and Huntington's disease.
Resumen de: CN121422231A
The invention discloses a multi-target compound preparation for targeted neuron autophagy repair as well as a preparation method and application thereof, and belongs to the technical field of neuropharmacology and pharmaceutical preparations. The compound preparation comprises an mTOR inhibitor Torrin 1, a lysosome function enhancer ursodesoxycholic acid, a neuroprotective agent coenzyme Q10 and alpha-lipoic acid according to a mass ratio of 1: 10: 5, and by synergistically adjusting autophagy initiation, autophagosome-lysosome fusion and neuron metabolism homeostasis, systematically repairing autophagy flux, efficiently removing beta amyloid protein and tau protein aggregates, and improving the autophagy efficiency. The mitochondrial function is improved. Sustained release is realized by adopting a sustained release microsphere technology, and the drug effect can be maintained for 14 days. Animal experiments show that protein aggregates in brains of mice suffering from the Alzheimer disease can be reduced by 70% or above, the cognitive function is remarkably improved, the safety is good, and a new choice is provided for treatment of neurodegenerative diseases.
Resumen de: NZ758484A
The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegerative diseases, including Alzheimer’s disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.
Resumen de: NZ799802A
The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegerative diseases, including Alzheimer’s disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.
Resumen de: NZ792513A
Aspects of the disclosure relate to compositions and methods useful for treating Huntington’s disease. In particular, the disclosure provides interfering nucleic acids (e.g., artificial mature miRNAs flanked by a miR-155 or a miR-30 backbone sequence) targeting the huntingtin gene (HTT) and methods of treating Huntington’s disease using the same.
Resumen de: CN121428061A
The invention belongs to the technical field of medicines, and particularly relates to a group of butyrylcholine esterase (BChE) inhibitors with high selectivity and a screening method thereof, in particular to two BChE specific inhibitors, namely methyl 4-hydroxybenzyl carbamate and moringa seed extract, which are screened from a moringa seed extract. The invention also relates to application of the BChE specific inhibitor in preparation of drugs for preventing or treating Alzheimer's disease. The invention provides a brand new strategy for efficiently screening the anti-Alzheimer disease medicine.
Nº publicación: WO2026021131A1 29/01/2026
Solicitante:
OCEAN UNIV OF CHINA [CN]
\u4E2D\u56FD\u6D77\u6D0B\u5927\u5B66
Resumen de: WO2026021131A1
Disclosed are an aromatic alkylamine ferroptosis inhibitor based on a butylphthalide structure, a preparation method therefor, and an application thereof. The chemical structural formula of the ferroptosis inhibitor is as shown in formula (1) or formula (2). The ferroptosis inhibitor is capable of inhibiting ferroptosis caused by a ferroptosis inducer, and reduces the level of intracellular reactive oxygen species. The ferroptosis inhibitor reduces neurological damage caused by cerebral ischemia-reperfusion, and alleviates symptoms of neurological disorders such as Alzheimer's disease and Parkinson's disease. Compared to the ferroptosis inhibitor Ferrostatin-1, the arylalkylamine compound exhibits better metabolic stability and is suitable for in-vivo efficacy evaluation. Therefore, the novel arylalkylamine compound provided by the present invention demonstrates great application value in the treatment of ferroptosis-related neurological disorders.
BOPI
Sede Electrónica
